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Abstract
Background: To identify best practices and quality improvement initiatives, we aimed to assess whether the
incidence of Periprosthetic Joint Infection (PJI) and treatment strategies differed across patients treated in
Australian, European and United States (US) hospitals.
Methods: Routinely collected administrative data for 41397 patients undergoing a primary total hip or knee
arthroplasty between July 2007-December 2010 across 22 hospitals were included. Patients were followed for 2 years
looking for PJI occurrence, defined as early (within 4 weeks) and late PJI, and surgical treatment during 2.5 years after
PJI diagnosis. Logistic and Poisson regression models were used to test for differences in PJI occurrence and treatment
strategies across the three geographical regions, adjusted for age, sex, joint and Elixhauser comorbidity groups.
Results: PJI occurrence varied from 1.4% in European to 1.7% in Australian patients, which were significantly higher
than US patients after adjustment for patient characteristics (OR 1.24 [1.01–1.52] and 1.40 [1.03–1.91] respectively). Early
PJIs varied between 0.3% in European to 0.6% in Australian patients, but adjusted rates were similar. Revision following
PJI was significantly lower in Australian than in US patients (OR 0.46 [0.25–0.86]) as were the total number of revisions
(RR 0.51 [0.36–0.71]) and number of surgical procedures (RR 0.60 [0.44–0.81]) used to treat PJI.
Conclusion: The overall PJI rate was significantly higher in Australian patients, but fewer procedures were needed to
treat these PJIs. Future research should reveal whether this reflects PJIs caught earlier or less severe when diagnosed,
and whether this is associated with the longer length of stay after primary arthroplasty in Australian hospitals.
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Background
Worldwide about two million total hip (THA) and total
knee arthroplasties (TKA) are performed annually, with the
majority in the United States and Europe [1, 2]. The number
of arthroplasties is expected to increase considerably over
the next decades, [3, 4] due to the ageing population, an in-
creasing prevalence of obesity, and the demand and expect-
ation of these procedures in increasingly younger patients
[5]. This increased burden on our healthcare systems will
have considerable societal and economic consequences [6].
Although these procedures are very effective in reducing
pain and improving functionality of patients, complications
do occur and have shown to vary between hospitals [7].
Periprosthetic Joint Infection (PJI) following primary THA
or TKA is one of the most devastating complications, with
rates typically around 1–2% and slightly higher for TKA
than THA [7–10]. The occurrence of PJI has huge impact
on the patient, such as an increased rate of mortality and/
or readmission to hospital [11] with the resulting experi-
ence of a PJI being a major trauma for which patients
would like psychological support [12]. Projections indicate
a three-fold increase of PJIs by the year 2030 [3, 13]. How-
ever, PJI rates may vary, not only between hospitals but also
between health care systems, and with respect to treatment
strategies used. By studying these variations, we may be
able to identify best practices and thus directions for quality
improvement. Furthermore, with the expected growth in
THA and TKA procedures to be performed in the coming
decades, the rise in antimicrobial resistance of organisms
and the increased complexity of patients being cared for,
the number of PJIs is likely to increase accordingly along
with significant costs to treat PJI [11, 14].
The aim of the present study is firstly to assess whether
PJI occurrence differs across patients treated in hospitals
from different geographical regions (Australia, Europe and
United States (US)), and secondly to examine whether treat-
ment strategies for PJI differ between these patient groups.
Methods
Patients
Patient data from the Global Comparators Project were used,
in which hospitals from various countries all over the world
share their experiences and compare their outcomes using
routinely collected administrative admission data. As previ-
ously described, diagnoses and procedures were combined
into groups and comorbidities were defined within this Pro-
ject, which were matched across countries to reconcile the
different coding systems being used [15]. For the present
study, all patients who underwent a primary THA or TKA in
the period July 2007-December 2010 were selected; data were
available for patients from 22 hospitals across six countries
(Australia, Belgium, Denmark, Netherlands, United Kingdom
(UK), and the US). We distinguished three geographical re-
gions: Australia (four hospitals), Europe (11 hospitals) and
United States (seven hospitals). The names of individual
hospitals contributing data are listed in the Additional file 1:
Table A. Patients receiving a primary THA or TKA with a
primary diagnosis of cancer in the same admission, that is
any C-code (ICD-10) or codes between 104 and 2097 (ICD-
9), were excluded.
Definitions
All patients with a procedure code for a primary THA or
TKA were followed over a 2-year period for the occurrence
of a PJI during subsequent admissions. The following codes
were used to define a PJI, as the primary or secondary diag-
nosis of an admission: 996.66 (ICD-9, for the Netherlands
996.6), T84.5 or T84.7 (ICD-10 and ICD-AM). These repre-
sent billable medical codes that can be used to indicate a
diagnosis on a reimbursement claim. Only those PJIs that
occurred within 2 years after the initial admission for the
primary THA or TKA were included. We distinguished
between early PJI (occurring within 4 weeks) and late PJI
(after 4 weeks) based on clinical relevance, as treatments
are likely to differ between these two groups.
The primary and secondary procedure codes of all ad-
missions in these patients were then examined for any
codes indicating a surgical treatment of the PJI, in a period
of 2.5 years after PJI diagnosis. Additional file 1: Table B
shows the codes used to identify the various possible treat-
ments in the different coding systems. For the analysis,
the placement of an antibiotic spacer was aggregated with
revision or resection arthroplasty, as some coding systems
were not able to distinguish between these groups and
even more, these procedures are used in various combina-
tions in clinical practice (i.e. the antibiotic spacer is put in
when the prosthesis is removed).
In addition, the following case-mix variables were col-
lected: age 70+ versus <70, gender and all 32 Elixhauser
comorbidity groups (yes/no variable) as identified from
the secondary diagnoses data.
Statistical analysis
The mean PJI occurrence among patients treated in hospi-
tals from the three regions with 95% confidence intervals
was calculated first. This was done separately for primary
THA or TKA, and separately for early and late PJI occur-
rence as defined above. Testing was then undertaken for
differences in PJI occurrence between the three regions after
adjustment for case-mix, using stepwise backwards logistic
regression analysis. The following factors were included as
possible confounding variables: age group, sex, Elixhauser
comorbidity groups, TKA versus THA, and region. Region
however, was mandatory for the model and so was not
eliminated as part of the stepwise backwards analysis. An
Elixhauser comorbidity group was only included if at least
10 patients with that comorbidity had also experienced a
PJI, to prevent unstable estimates and improve model fit.
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Model fit was examined using both the C-statistic and the
Nagelkerke R-squared. The same analysis was done for early
PJI occurrence.
To assess whether treatment for PJI differed between
patients from hospitals in different regions, we looked at
the differences in the surgical procedure following the PJI.
First we looked at revision following PJI using backwards
logistic regression analysis within patients with a PJI
diagnosis, with the same variables included as above and re-
vision/resection (yes/no) as the dependent variable. Region
was a mandatory factor in the model. However, revision
surgery (i.e. one-stage revision) or resection arthroplasty
surgery (i.e. removal of implant) as the first surgical proced-
ure may indicate a more aggressive approach, compared
with irrigation and debridement as the first procedure and
so was subject to further sensitivity analysis with a further
condition being that revision/resection (yes/no) was
performed as the first surgical procedure as the dependent
variable. The same independent variables as above were
included and region was again a mandatory factor in the
model. The same analysis was done with irrigation and
debridement (yes/no) as the first surgical procedure.
But even if the first surgical procedure is more aggressive,
this may still be a more effective course of action if it means
that the patient undergoes fewer procedures. Therefore, the
total number of surgical procedures used to treat PJI across
patients from hospitals in the three regions was also exam-
ined. This was done using Poisson regression analysis, with
region mandated in the model and using the same case-
mix variables mentioned above. The same analysis was
done for the total number of revisions/resections, to assess
whether a less invasive initial approach might still result in
more invasive procedures being necessary.
In all analyses, a p-value < 0.05 was considered to be
statistically significant.
Results
Data from 22 hospitals across the three geographical regions
were included, covering 41397 primary procedures (Table 1).
Patient characteristics varied between regions and in
particular the percentage of patients with any comorbidities
being much higher in the US. The length of stay in the US
was much lower in the admission when the primary arthro-
plasty took place (on average 9 days shorter than Australia).
Crude PJI rates were highest in Australian patients
(1.7%) and lowest in Europe (1.4%). Figure 1 shows that
the higher PJI rate in Australian patients was mainly in
early PJIs occurring within 4 weeks, but that late PJI rates
were similar. After adjustment for differences in patient
characteristics, the likelihood of a PJI diagnosis was sig-
nificantly higher in both Australian and European patients
compared to the US (Table 2). Table 2 also shows that the
likelihood of a PJI was significantly increased for male pa-
tients with various types of comorbidities undergoing
TKA. PJI was less likely to be diagnosed in elderly patients
(70+ years of age) independent from any comorbidity,
which probably reflects a healthy selection of elderly
patients without comorbidity undergoing THA or TKA or
alternatively, these patients receive antibiotic suppression
therapy to prevent PJI because they are too frail to
undergo revision surgery. Looking only at early PJI, rates
were similar as the US after adjustment for patient charac-
teristics (OR 1.46 [0.86–2.47] for Australia and 0.98
[0.67–1.42] for Europe).
Table 3 shows that after adjustment for differences in
patient characteristics, chances of a revision as treatment
following PJI diagnosis are significantly lower in Australian
patients (54% lower). Figure 2 shows that treatment strat-
egies seem to differ across regions with irrigation and de-
bridement more often used as first treatment following PJI
diagnosis in Australia and revision more often as first treat-
ment in the US. After adjustment for differences in patient
characteristics, chances of a revision as first treatment
following PJI diagnosis was significantly lower in Australia
(OR 0.50 [0.28–0.92]) and similar in Europe (OR 0.71
[0.48–1.06]) compared to the US. Differences in irrigation
and debridement as first treatment were not statistically
different after adjustment for patient characteristics (data
not shown). Looking at the number of procedures, both the
Table 1 Patient characteristics, PJI rate and treatment across 3
regions
Australia Europe US Total
Hospitals
Number of hospitals 4 11 7 22
Arthroplasties
Number of arthroplasties 3705 26993 10699 41397
% Hip 47% 50% 46% 49%
Patient characteristics at primary arthroplasty
Average age 68.4 68.2 62.3 66.7
Median age 70 69 63 68
% Females 62% 61% 60% 61%
% with 1 or more comorbidities 42% 56% 80% 61%
Average number of comorbidities 0.8 0.9 1.7 1.1
Median number of comorbidities 0 1 2 1
Length of stay (LOS) of primary arthroplasty admission
Average LOS in arthroplasty spell 12.4 7.7 3.3 7.0
Median LOS in arthroplasty spell 7 6 3 5
% patients in upper quartile LOS 46% 33% 2% 26%
Prosthetic joint infections (PJI)
PJI rate within 2 years 1.7% 1.4% 1.5% 1.4%
Treatment of prosthetic joint infection within 2.5 years
Average number of procedures 0.9 1.3 1.6 1.4
Median number of procedures 1 1 1 1
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number of revisions and the total number of surgical
procedures following PJI diagnosis are significantly lower in
Australia after adjustment for differences in patient charac-
teristics (Fig. 3). Europe also has significantly fewer revi-
sions following PJI diagnosis compared to the US, but the
total number of surgical procedures does not differ
significantly.
Discussion
The present study has shown that PJI after primary THA
and TKA is diagnosed more frequently in Australian and
European patients than in US patients, but that occurrence
of early PJI within 4 weeks is similar. The PJI rate was sig-
nificantly higher in patients with various types of comorbid-
ities as well as after knee arthroplasty. Treatment strategies
following PJI were also different across these three regions,
with revisions being less frequently used as first treatment
in Australia as well as fewer revisions and a lower total
number of surgical procedures. Europe also had fewer revi-
sions following PJI diagnosis but the same total number of
surgical procedures as the US. The hypothesis that would
fit these findings is that PJIs in Australia are caught earlier
or are less severe when diagnosed resulting in fewer surgi-
cal procedures being necessary, which should be further
investigated.
Limitations of our study include the use of administra-
tively collected data which may overestimate or underesti-
mate the presence of comorbidities and complications,
with differences across hospitals and health care systems
due to different coding practices. In the present study the
average number of reported comorbidities in patients was
clearly higher for US patients, most likely due to the finan-
cial incentives associated with coding [16], which may
Fig. 1 Crude early Periprosthetic Joint Infection (PJI) rate (<4 weeks) versus late PJI rate (<2 years) across 3 regions
Table 2 Influence of patient characteristics and region on
Periprosthetic Joint Infection (PJI) rate
Variable Odds Ratio
[95% CI]
Age > =70 years 0.75 [0.63-0.89]
Sex (Males versus Females) 1.38 [1.17–1.63]
Comorbidities
Cardiac arrhythmias (yes/no) 1.32 [0.99–1.74]
Congestive heart failure (yes/no) 1.58 [0.98–2.53]
Rheumatoid arthritis, collagen or
vascular disease (yes/no)
1.96 [1.39–2.75]
Diabetes uncomplicated (yes/no) 1.28 [1.00–1.64]
Coagulopathy (yes/no) 2.28 [1.29–4.03]
Fluid and electrolyte disorders (yes/no) 1.63 [1.15–2.30]
Depression (yes/no) 2.04 [1.46–2.86]
Joint (knee versus hip) 1.52 [1.28–1.79]
Region
Australia versus US 1.40 [1.03–1.91]
Europe versus US 1.24 [1.01–1.52]
Significant differences are indicated in bold; Model fit: C statistic = 0,61
Nagelkerke R2 = 0,018
Table 3 Influence of patient characteristics and region on
having a revision as surgical treatment following Periprosthetic
Joint Infection (PJI)
Variable Odds Ratio [95% CI]
Age > =70 years 0.62 [0.43–0.87]
Comorbidities
Obesity (yes/no) 0.63 [0.36–1.12]
Fluid and electrolyte disorders (yes/no) 0.43 [0.22–0.86]
Region
Australia versus US 0.46 [0.25–0.86]
Europe versus US 0.77 [0.51–1.16]
Significant differences are indicated in bold; Model fit: C statistic = 0,62
Nagelkerke R2 = 0,053
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Fig. 2 Crude rates of first treatment of Periprosthetic Joint Infection (PJI) across 3 regions
Fig. 3 Difference between regions in number of surgical procedures and number of revisions for Periprosthetic Joint Infection (PJI), adjusted for
differences in patient characteristics
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result in PJI rates in the US being underestimated after ad-
justment for these reported comorbidities. However, reim-
bursement of health services in Australia also depends on
clinical coding [17], but did not result in a higher number
of reported comorbidities, so that it does not seem likely
that this will explain the results entirely. Another issue is
the ability to correctly identify PJI from administrative
data. Lange et al have recently shown an 85% positive pre-
dictive value for periprosthetic hip joint infection using
administrative discharge registers from Denmark, which
slightly increased to 86% when combined with an
infection-specific surgical procedure code [18]. Bozic et al
also argued that diagnoses like PJI are less influenced by
coding practices and found 99% agreement after medical
record validation [7]. Related to this, variation in the def-
inition of PJI across centres could have influenced our
findings. However, given the use of clinical admission data
with ICD9 or ICD10 coding, only those PJIs serious enough
to warrant readmission will have been included, and less
subject to variation in applied definitions. Finally, bias in
procedures to treat PJI is far less likely but nevertheless
there was still variation in surgical treatment strategy
amongst the three health care systems, with fewer proce-
dures required to treat PJI in Australia. When checking all
the data for incomplete follow-up time after PJI diagnosis
(i.e. less than 2.5 years), it was found that 4% of the PJIs in
Europe had incomplete follow-up, 0% in the US and 0% in
Australia. As these percentages are very low, it is not likely
to affect the results to a great extent. If anything, this means
that the number of revisions following PJI might have been
underestimated in Europe, so that the difference with the
US may be smaller in reality, but it cannot explain the dif-
ference between Australia and the US. The number of pri-
mary arthroplasties per patient was also checked, to
investigate the possibility that another “primary arthro-
plasty” may have been coded for when in reality a revision
is performed. However, numbers of more than two primary
arthroplasties in a patient were extremely low, particularly
in the US (0.04%, versus 0.05% in Australia and 0.07% in
Europe) so this also is not likely to have influenced our re-
sults. Finally we checked the extent to which PJIs were di-
agnosed in the same admission as the primary arthroplasty,
whereas only PJIs in subsequent admissions were counted
in the primary analysis. As expected, rates were low (0.5%
for Australia, 0.3% for Europe and 0.1% for US) so that the
difference in PJI between patients from different regions
might even have been underestimated.
It is important to note that the study findings are only
based on a limited number of hospitals within the countries
and regions examined. As each centre was a large academic
medical unit, outcomes between centres included in our
study will be fairly comparable with respect to their patient
population, but may differ from other units in the selected
countries. Therefore it is possible that observed differences
in this study are only found among complex patients typic-
ally treated in academic centres but are not representative
for patients treated in other hospitals in these regions. Still,
the overall PJI rate of 1.4% within 2 years after the primary
arthroplasty and 0.4% of early PJIs within 4 weeks fits well
in the reported range of PJI in previous studies, when dif-
ferences in duration of follow-up between studies are taken
into account [7, 8, 10]. Another reason for discrepancies
with previously reported rates is that some studies only in-
clude PJIs with a related procedure [7, 8]. Excluding PJI
with an unrelated procedure in the present study, would re-
sult in similar PJI rates around 1% as reported in those
studies. Furthermore, the factors identified to increase the
likelihood of a PJI such as coagulopathy and rheumatoid
arthritis as well as being higher after primary TKA, are con-
sistent with previous reports [9, 19, 20].
Conclusions and implications
What the present study has shown for the first time is that
both PJI diagnosis and the associated treatment strategy
seem to differ across patients treated in different health care
systems. Discussions among collaborating hospitals did not
suggest any difference in preoperative infection prophylaxis
strategy but no patient level data were available to substan-
tiate this. Combining the significantly higher PJI rate in
Australia with the less aggressive treatment strategy of
revisions being less often the first treatment following PJI
and fewer surgical procedures, results in the hypothesis of
less severe PJIs when diagnosed or PJIs caught earlier. This
may be associated with the considerable longer length of
stay in Australian hospitals, which may indicate (early signs
of) the PJI or alternatively, being more of a ‘standard
duration’ in this health care system but thereby enabling
identification of the PJI compared with US hospitals dis-
charging patients early so early PJIs may not be identified.
This is supported by the difference in PJI rates diagnosed in
the same admission as the primary arthroplasty. Diagnosing
the PJI earlier is also likely to affect the treatment strategy,
that is requiring either less aggressive or fewer procedures
to be treated adequately. Another explanation may be an
active surveillance system being present as for instance the
Victorian Healthcare Associated Infection Surveillance
System (VICNISS) reporting a significant reduction of
surgical site infections over time including a reduction in
deep surgical site infections [21]. However, similar surveil-
lance systems are also present in the United States and in
Europe (e.g. the CDC and the ECDC), so that it does not
seem likely that this would explain the observed difference
between regions. Finally, the higher number of revisions
and surgical procedures being performed in the US may be
due to the time of presentation or the patients’ clinical
status at the time of presentation, but another thing to
consider is that it may not just be clinical practice but also
an effect of remuneration for procedures across the
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different health care systems, given for instance the higher
fees for hip replacements in the US than in Australia and
European countries [22].
An important question is whether the initial longer
length of stay for THA and TKA in Australia, in fact is a
cost-effective approach if it results in complications like PJI
being caught earlier and fewer readmissions and treatments
being required. Multiplying the initial longer length of stay
in Australia compared to the US from Table 1, with the bed
day costs of about £400 [23] and divided by the difference
in number of revisions, this would amount to £410.241
health care costs per prevented revision in Australia. For
Europe, health care costs would be £363.866 higher. These
costs are likely to be overestimated as only hospital bed
days were included in this study and patients in the US
routinely go to rehabilitation centres after leaving the hos-
pital. Assuming the same total length of stay in the US as
in Europe, would still amount to £213.366 per prevented
revision in Australia. These costs exceed the average costs
for revision surgery of £25.974. [23, 24] Including societal
costs by assuming that 50% of patients would be absent
from work for 8 weeks because of the revision, amounting
to £1.400 per week, costs in Australia and Europe were still
considerably (£378.667 and £332.292 respectively) higher
than the costs for revision surgery. Assuming a threshold of
£30.000 per Quality Adjusted Life Years (QALY) for a cost-
effective intervention, this would mean that 12,6 QALY’s
have to be gained by preventing revisions, for the
Australian strategy to be cost-effective compared to the US
(11,1 QALY’s for Europe). This is highly unlikely, given that
even under assumptions of temporary health loss of 50%
during 6 months and 20% permanent health loss for 10% of
the patients, this would only amount to about 1 QALY
gained. Our results thus have important implications for
future directions in clinical practice, but also strongly
illustrate the value of international collaboratives allowing
us to compare outcomes, learn from each other, and enable
improvements in quality of care.
Additional file
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